Induction of the RNA regulator LIN28A is required for the growth and pathogenesis of RESTless breast tumors - PubMed (original) (raw)
Induction of the RNA regulator LIN28A is required for the growth and pathogenesis of RESTless breast tumors
Kearney T W Gunsalus et al. Cancer Res. 2012.
Abstract
The transcription factor RE1 silencing transcription factor (REST) is lost in approximately 20% of breast cancers. Although it is known that these RESTless tumors are highly aggressive and include all tumor subtypes, the underlying tumorigenic mechanisms remain unknown. In this study, we show that loss of REST results in upregulation of LIN28A, a known promoter of tumor development, in breast cancer cell lines and human breast tumors. We found that LIN28A was a direct transcriptional target of REST in cancer cells and that loss of REST resulted in increased LIN28A expression and enhanced tumor growth both in vitro and in vivo, effects that were dependent on heightened LIN28A expression. Tumors lacking REST expression were locally invasive, consistent with the increased lymph node involvement observed in human RESTless tumors. Clinically, human RESTless breast tumors also displayed significantly enhanced LIN28A expression when compared with non-RESTless tumors. Our findings therefore show a critical role for the REST-LIN28A axis in tumor aggression and suggest a causative relationship between REST loss and tumorigenicity in vivo.
©2012 AACR.
Figures
Figure 1
REST knockdown enhances tumorigenicity of cells in culture. A–B, Western blot showing REST knockdown in MCF7 and MDA-MB-231 cells. C–E, Plating efficiency of RESTlow and RESTnorm MCF7, MCF10A and MDA-MB-231 cells in a clonogenic assay (p≤0.050). F–G, Soft agar colony formation assay comparing anchorage-independent growth of RESTlow versus RESTnorm MCF7 and MCF10A cells (p≤0.050).
Figure 2
REST knockdown increases the aggressiveness of MCF7 tumor growth in nude mouse xenografts. A, 106 control (RESTnorm) or REST knockdown (RESTlow) MCF7 cells were injected subcutaneously into the mammary fat pads of female athymic nude mice. Tumor incidence was monitored weekly, and is significantly higher for RESTlow versus RESTnorm cells (p=0.0022). B, Tumor burden in the mammary fat pads is significantly larger in RESTlow versus RESTnorm tumors (p<0.0001). C, 106 control (RESTnorm) or REST knockdown (RESTlow) MCF7 cells were injected subcutaneously into the flanks of female athymic nude mice. Tumor incidence upon injection into flank is significantly higher for RESTlow versus RESTnorm MCF7 cells (p=0.0382). D, Tumor burden in flanks is significantly larger in RESTlow versus RESTnorm tumors (p=0.0016). E–G, Bright field photomicrographs of H&E stained sections of RESTlow tumors. Representative images show the histopathology (E) and local invasion (F) observed in these tumors; arrows in (F) indicate muscle fibers incorporated into the tumor. G, RESTlow tumor and adjacent mammary fat pad; arrows indicate lympho-vascular invasion.
Figure 3
REST is a direct transcriptional repressor of LIN28A in breast cancer cells. A, LIN28A mRNA in RESTlow and RESTnorm T47D cells was analyzed by qPCR and normalized to actin (p=0.05). B, Western blot for LIN28A and β-actin (loading control) in RESTlow and RESTnorm T47D cells. C, LIN28A mRNA in RESTlow and RESTnorm MCF7 cells was analyzed by qPCR and normalized to actin (p=0.0053). D, Immunofluorescent staining for LIN28A in RESTnorm and RESTlow MCF7 cells. E, Chromatin immunoprecipitations (ChIP) in MCF7 cells with anti-REST antibody and IgG (sham). DNA analyzed by qRT-PCR with primers in the LIN28 and BDNF (positive control) promoter regions; negative control (NC) lacks RE1 site. F, ChIP in MCF7 cells using anti-REST or anti-G9a antibody, and IgG (sham). DNA was analyzed via qRT-PCR using primers up- and downstream of TSS. G–I, Schematic representation of the LIN28 promoter region showing placement of primers used to clone the LIN28 promoter region including (+RE1) or excluding (−RE1) the REST binding site into a pGL3 luciferase reporter plasmid, which was transfected into RESTnorm and RESTlow MCF7 (F) and HEK (G) cells. Luciferase expression was normalized to renilla. J, LIN28A immature and processed mRNA in RESTlow versus RESTnorm tumors measured by qPCR (p≤0.04). Housekeeping genes showed no significant difference.
Figure 4
LIN28A is necessary and sufficient for RESTlow phenotypes in vitro. A, Immunoblot for LIN28A or β-actin (loading control) in control (LIN28Anorm) or LIN28A knockdown (LIN28Alow) MCF7 cells. B, Soft agar colony formation of RESTnorm and RESTlow MCF7 cells with and without anti-LIN28 shRNA (LIN28low) (p=0.0383). C–D, Growth of RESTnorm and RESTlow MDA-MB-231 cells with and without anti-LIN28 shRNA (LIN28low) in high (C, 10%) or low (D, 2.5%) serum (72h, p≤0.05). E–G, Lentiviral delivery of a LIN28A expression construct was used to generate LIN28 over-expressing MCF7 cells; expression was verified by western blot (E). Clonogenicity (F) and soft agar colony formation (G) were measured (p≤0.05).
Figure 5
LIN28A contributes to the tumorigenicity of RESTlow MCF7 cells in mice. 106 RESTlow/LIN28Anorm or RESTlow/LIN28Alow MCF7 cells were injected subcutaneously into the mammary fat pads of athymic nude mice, and tumor incidence and growth were monitored weekly. A–B Tumor incidence (A, p=0.020) and burden (B, p=0.0002) are decreased upon LIN28A knockdown.
Figure 6
LIN28A mRNA is increased in human RESTless tumors. A–B, Box and whisker plot of fold median LIN28A mRNA expression in RESTless and REST-containing (“RESTfl”) breast tumors from datasets GSE2034 (A, p<0.0001) and GSE2990 (B, p=0.0050). Lines of the box represent 75th, 50th and 25th percentiles; whiskers represent 90th and 10th percentile of LIN28A expression in each group.
Similar articles
- LIN28A-stabilized FBXL19-AS1 promotes breast cancer migration, invasion and EMT by regulating WDR66.
Zhang Y, Xiao X, Zhou W, Hu J, Zhou D. Zhang Y, et al. In Vitro Cell Dev Biol Anim. 2019 Jun;55(6):426-435. doi: 10.1007/s11626-019-00361-4. Epub 2019 May 28. In Vitro Cell Dev Biol Anim. 2019. PMID: 31140103 - Lin28A activates androgen receptor via regulation of c-myc and promotes malignancy of ER-/Her2+ breast cancer.
Shen H, Zhao L, Feng X, Xu C, Li C, Niu Y. Shen H, et al. Oncotarget. 2016 Sep 13;7(37):60407-60418. doi: 10.18632/oncotarget.11004. Oncotarget. 2016. PMID: 27494865 Free PMC article. - The transcription factor REST is lost in aggressive breast cancer.
Wagoner MP, Gunsalus KT, Schoenike B, Richardson AL, Friedl A, Roopra A. Wagoner MP, et al. PLoS Genet. 2010 Jun 10;6(6):e1000979. doi: 10.1371/journal.pgen.1000979. PLoS Genet. 2010. PMID: 20548947 Free PMC article. - Hepatitis B virus X protein upregulates Lin28A/Lin28B through Sp-1/c-Myc to enhance the proliferation of hepatoma cells.
You X, Liu F, Zhang T, Lv N, Liu Q, Shan C, Du Y, Kong G, Wang T, Ye L, Zhang X. You X, et al. Oncogene. 2014 Jan 23;33(4):449-60. doi: 10.1038/onc.2012.618. Epub 2013 Jan 14. Oncogene. 2014. PMID: 23318446 - Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms.
Piskounova E, Polytarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, Hagan JP, Iliopoulos D, Gregory RI. Piskounova E, et al. Cell. 2011 Nov 23;147(5):1066-79. doi: 10.1016/j.cell.2011.10.039. Cell. 2011. PMID: 22118463 Free PMC article.
Cited by
- Overexpression of REST Represses the Epithelial-Mesenchymal Transition Process and Decreases the Aggressiveness of Prostate Cancer Cells.
Indo S, Orellana-Serradell O, Torres MJ, Castellón EA, Contreras HR. Indo S, et al. Int J Mol Sci. 2024 Mar 15;25(6):3332. doi: 10.3390/ijms25063332. Int J Mol Sci. 2024. PMID: 38542313 Free PMC article. - MAGIC: A tool for predicting transcription factors and cofactors driving gene sets using ENCODE data.
Roopra A. Roopra A. PLoS Comput Biol. 2020 Apr 6;16(4):e1007800. doi: 10.1371/journal.pcbi.1007800. eCollection 2020 Apr. PLoS Comput Biol. 2020. PMID: 32251445 Free PMC article. - LIN28A-stabilized FBXL19-AS1 promotes breast cancer migration, invasion and EMT by regulating WDR66.
Zhang Y, Xiao X, Zhou W, Hu J, Zhou D. Zhang Y, et al. In Vitro Cell Dev Biol Anim. 2019 Jun;55(6):426-435. doi: 10.1007/s11626-019-00361-4. Epub 2019 May 28. In Vitro Cell Dev Biol Anim. 2019. PMID: 31140103 - Identification of RE1-Silencing Transcription Factor as a Promoter of Metastasis in Pancreatic Cancer.
Jin H, Liu P, Kong L, Fei X, Gao Y, Wu T, Sun D, Tan X. Jin H, et al. Front Oncol. 2019 Apr 16;9:291. doi: 10.3389/fonc.2019.00291. eCollection 2019. Front Oncol. 2019. PMID: 31041193 Free PMC article. - Drosophila Jak/STAT Signaling: Regulation and Relevance in Human Cancer and Metastasis.
Trivedi S, Starz-Gaiano M. Trivedi S, et al. Int J Mol Sci. 2018 Dec 14;19(12):4056. doi: 10.3390/ijms19124056. Int J Mol Sci. 2018. PMID: 30558204 Free PMC article. Review.
References
- Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, et al. A genetic screen for candidate tumor suppressors identifies REST. Cell. 2005 Jun 17;121(6):837–48. - PubMed
- Chong JA, Tapia-Ramirez J, Kim S, Toledo-Aral JJ, Zheng Y, Boutros MC, et al. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell. 1995 Mar 24;80(6):949–57. - PubMed
- Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science. 1995 Mar 3;267(5202):1360–3. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials